


PHARMACEUTICAL 2021

Nkarta Inc. Rank 37 of 402







PHARMACEUTICAL 2021



Nkarta Inc. Rank 37 of 402

The relative strengths and weaknesses of Nkarta Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nkarta Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Nkarta Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 260%, being 213% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	318,835
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,831
Liabilities, Non-Current	7,599
Other Assets	9,465
Other Compr. Net Income	5.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-39,853
Other Revenues	0
Property and Equipment	9,350
Research and Development	36,220
Selling, General and Administrative Expense	15,288

Output Variable	Value in 1000 USD
Assets	337,650
Liabilities	16,430
Expenses	51,508
Revenues	0
Stockholders Equity	321,220
Net Income	-91,361
Comprehensive Net Income	-91,358
Economic Capital Ratio	260%

